FDA Embarks on Plant Medicine Journey For Mental Health, PTSD Solutions 

In late April, President Trump appeared in the Oval Office press conference flanked by military veterans, HHS Secretary Kennedy, and podcaster/comedian Joe Rogan.   

An Executive Order announcement followed, stating:

“Psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy….It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”

The move has been welcomed by many, especially veterans, who have been historically left behind by the Department of Veterans Affairs. A ProPublica analysis of 313 studies conducted by the agency’s inspector general in recent years shows repeated failures in behavioral care.

Over two decades, the U.S. Department of Veterans Affairs has documented a staggering rate of approximately 6,000 veteran suicides per calendar year since 2001.

In addition, the long-standing failure of the legacy pharmaceutical drug solutions to mental health has been strikingly clear. More than 15 million Americans live with serious mental illness, while suicide rates have risen by 30% over the last two decades.

Despite a corporate-friendly environment where harms were hidden, regulatory agencies were captured by revolving door conflicts of interest, and benefits exaggerated to secure market share, drug classes like antidepressant SSRIs have been a net failure for society.

Enter a new class of therapy. Ancestral plant medicine and their derivatives in the form of MDMA, ibogaine and psilocybin.

Less than a week after Trump’s EO, the FDA issued national priority vouchers to three companies studying Psilocybin for treatment-resistant depression and major depressive disorder and Methylone for post-traumatic stress disorder (PTSD).

These vouchers function as an “ultra-fast-track” review, meaning FDA review periods are dramatically cut down to 1–2 months rather than the standard 10+ months. The agency also authorized an early-stage clinical trial for noribogaine hydrochloride (an ibogaine derivative) as a potential treatment for alcohol use disorder.

While the feds pivot to allow plant medicine, state level movement sees the Texas legislature pony up a record $50 million research grant to study ibogaine, a psychedelic made from a native West Africa shrub, as a treatment for opioid addiction, PTSD and other conditions.

Far from a reckless misadventure into dangerous controlled substances, science and research has increasingly backed the benefits of plant medicines compounds.

Perhaps the the best, robust evidence for psilocybin (the active compound in “magic mushrooms”) comes from randomized controlled trials (RCTs) and meta-analyses of psilocybin-assisted therapy—typically 1–2 high doses (e.g., 20–30 mg/70 kg or fixed 25 mg) given with psychological support/preparation and integration sessions.

A 2024 systematic review and meta-analysis of the efficacy of psilocybin for treating symptoms of depression found:

-A “moderate-to-large effect size” on depression scores (which measure how bad someone’s depression symptoms are).

-A doubled response rate (a person is counted as a “responder” if their depression score drops by at least 50% from the start of the study.)

-A nearly tripled remission rates (A person reaches remission when their depression score drops to a very low level, meaning they have few or no significant depression symptoms anymore.)

The larger, beneficial effects were found in what’s called ‘secondary depression’ (e.g., depression linked to cancer or other serious illness) which is particularly notable because traditional antidepressants often perform poorly or are contraindicated in these populations.

A pair of double-blind, placebo-controlled studies of adults with moderate to severe PTSD looked at the effects and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy and found the following:

1.) Mitchell et al. (2021) In people with severe, long-standing PTSD (often with other issues like depression or trauma history), 3 MDMA-assisted therapy sessions produced large, clinically meaningful improvements far better than therapy alone. 67% of the MDMA group no longer met PTSD diagnosis criteria vs 32% placebo while

Full remission (no diagnosis + very low symptoms) say 33% in the MDMA group vs 5% in the placebo group.

2.) Mitchell et al. (2023) This second large trial confirmed the strong benefits seen in the first study, even in a broader and more diverse group of people with moderate-to-severe PTSD. MDMA-assisted therapy again showed robust, clinically meaningful results with a good safety profile in a controlled therapeutic setting. 71.2% of participants in the MDMA group no longer met the PTSD diagnosis vs 47.6% in the placebo group, while 46.2% in the MDMA group experienced full remission vs 21.4% in the placebo group.

For the ibogaine group, particularly focused on veterans, a 2024 study published in Nature Medicine is considered the highest-quality and most-cited study. 30 male Special Operations Forces (SOF) veterans took part with predominantly mild Traumatic brain injury (TBI) from repeated blast/combat exposure (high chronic stress/trauma load).

Treatment involved a single oral dose of ibogaine + magnesium (for cardiac protection) at a clinic in Mexico, with preparatory/integration support and complementary modalities (e.g., yoga, meditation).

67% of the MDMA group no longer met PTSD diagnosis criteria while

33% experienced full remission (no diagnosis + very low symptoms) vs 5% in the placebo group.

A key and nuanced objective for longterm viability and success in the rollout of these strong medicines will be the institutional respect for their unique properties regarding the  preparatory and integration support. Unlike the pharmaceutical ‘a pill for every ill’ paradigm, plant medicines often work intimately alongside and within specific spiritual and ritual practices which enhance and support the medicine’s effects.

Can researchers and the FDA account for this subtle yet profound shift in what could be a game-changing, holistic therapeutic class of medicines?

Speaking to The HighWire regarding the Trump Executive Order, founder and director of the Ayahuasca Foundation, Carlos Tanner, stated:

“[The] directive is an incredible opportunity to deepen our understanding of these sacred medicines that have been used by indigenous tribes for generations and a big step closer to the paradigm shift needed for Western culture.

As the American medical and scientific community evolve their understanding of these healing modalities my hope is that they honor and incorporate the ancestral wisdom and spiritual practice that brought these plant medicine traditions to our awareness.”